
Since tanking in early August, shares of Eli Lilly and Company (NYSE: LLY) have roared back with a vengeance. The world’s most valuable healthcare stock plummeted around 14% on Aug. 7 after releasing somewhat disappointing data on its developmental oral GLP-1 drug, orforglipron. Eli Lilly shares have surged around 40% from that August dip.
Aiding the stock’s rise was Lilly’s Q3 2025 earnings report, released on Oct. 30. Shares rose around 10% over the three following trading days. Below, we’ll break down Eli Lilly’s latest earnings and gain an updated outlook on the stock. Overall, how should investors view the short- and long-term potential of Eli Lilly shares?